705 related articles for article (PubMed ID: 35626663)
1. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
5. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis.
Coward WR; Watts K; Feghali-Bostwick CA; Knox A; Pang L
Mol Cell Biol; 2009 Aug; 29(15):4325-39. PubMed ID: 19487460
[TBL] [Abstract][Full Text] [Related]
6. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.
Coward WR; Watts K; Feghali-Bostwick CA; Jenkins G; Pang L
Mol Cell Biol; 2010 Jun; 30(12):2874-86. PubMed ID: 20404089
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Sanders YY; Hagood JS; Liu H; Zhang W; Ambalavanan N; Thannickal VJ
Eur Respir J; 2014 May; 43(5):1448-58. PubMed ID: 24603818
[TBL] [Abstract][Full Text] [Related]
8. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
Liu N; He S; Ma L; Ponnusamy M; Tang J; Tolbert E; Bayliss G; Zhao TC; Yan H; Zhuang S
PLoS One; 2013; 8(1):e54001. PubMed ID: 23342059
[TBL] [Abstract][Full Text] [Related]
9. HDAC8 inhibition ameliorates pulmonary fibrosis.
Saito S; Zhuang Y; Suzuki T; Ota Y; Bateman ME; Alkhatib AL; Morris GF; Lasky JA
Am J Physiol Lung Cell Mol Physiol; 2019 Jan; 316(1):L175-L186. PubMed ID: 30358439
[TBL] [Abstract][Full Text] [Related]
10. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts.
Huang SK; Scruggs AM; Donaghy J; Horowitz JC; Zaslona Z; Przybranowski S; White ES; Peters-Golden M
Cell Death Dis; 2013 May; 4(5):e621. PubMed ID: 23640463
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
Hyndman KA
Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibition downregulates collagen 3A1 in fibrotic lung fibroblasts.
Zhang X; Liu H; Hock T; Thannickal VJ; Sanders YY
Int J Mol Sci; 2013 Sep; 14(10):19605-17. PubMed ID: 24084714
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylases.
Huang Y; Shaw PG; Davidson NE
Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology.
Joanna F; van Grunsven LA; Mathieu V; Sarah S; Sarah D; Karin V; Tamara V; Vera R
J Cell Mol Med; 2009 Sep; 13(9B):2990-3005. PubMed ID: 19583816
[TBL] [Abstract][Full Text] [Related]
18. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
Bai G; Wei D; Zou S; Ren K; Dubner R
Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
